Kazia Therapeutics (KZIA) Total Non-Current Liabilities (2009 - 2025)
Kazia Therapeutics (KZIA) posted Total Non-Current Liabilities of $178697.5 for Q4 2025, down 9.48% on a QoQ basis from $197405.8 in Q2 2025, and down 94.75% year-over-year from $3.4 million in Q4 2024.
Kazia Therapeutics (KZIA) has 14 years of Total Non-Current Liabilities data on file, last reported at $178697.5 in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 94.75% year-over-year to $178697.5; the TTM figure through Dec 2025 stood at $178697.5 (down 94.75% YoY), while the FY2025 annual figure was $197405.8, down 94.84% from the prior year.
- Total Non-Current Liabilities declined to $178697.5 in Q4 2025, from $197405.8 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.2 million in Q2 2021 and bottomed at $178697.5 in Q4 2025.
- A 5-year average of $4.7 million and a median of $5.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 261.49% — and 2025, when it tumbled 94.84%.
- Year by year, Total Non-Current Liabilities stood at $9.2 million in 2021, then decreased by 23.56% to $7.0 million in 2022, then dropped by 27.76% to $5.1 million in 2023, then sank by 32.76% to $3.4 million in 2024, then tumbled by 94.75% to $178697.5 in 2025.
- The last three Total Non-Current Liabilities figures came in at $178697.5 (Q4 2025), $197405.8 (Q2 2025), and $3.4 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Kazia Therapeutics | 1.55 Bn | 1.55 Bn | - | 178,697.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 178,697.54 |
| Jun 30, 2025 | 197,405.85 |
| Dec 31, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.83 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Jun 30, 2023 | 5.66 Mn |
| Dec 31, 2022 | 7.01 Mn |
| Jun 30, 2022 | 7.80 Mn |
| Jun 30, 2021 | 9.17 Mn |
| Dec 31, 2020 | 3.81 Mn |
| Jun 30, 2020 | 2.54 Mn |
| Dec 31, 2019 | 3.52 Mn |
| Jun 30, 2019 | 3.56 Mn |
| Dec 31, 2018 | 3.45 Mn |
| Jun 30, 2018 | 3.82 Mn |
| Jun 30, 2017 | 3.90 Mn |
| Dec 31, 2016 | 3.74 Mn |
| Jun 30, 2016 | 3.87 Mn |
| Jun 30, 2012 | 7,073.74 |
| Dec 31, 2011 | 105,149.22 |
| Jun 30, 2011 | 110,415.11 |
| Dec 31, 2010 | 150,116.34 |
| Jun 30, 2010 | 134,373.52 |
| Dec 31, 2009 | 214,512.69 |
| Jun 30, 2009 | 179,111.53 |